Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant chemotherapy for colorectal cancer

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Colorectal cancer is the second leading cause of cancer death in Western countries. If surgery remains the only cure, recurrence rates for colon cancer range from 30% to 60% for stage III tumors. Adjuvant chemotherapy is the standard treatment for stage III colon tumors and consists of monthly administration of bolus 5-fluorouracil and leucovorin for 5 consecutive days a month over a 6-month period (Mayo regimen). Adjuvant chemotherapy for stage II colon cancer remains controversial, and its administration is not routinely recommended except in certain high-risk and selected patients. Immunotherapy, new drug-based therapies or combinations, and cyclooxygenase-2 inhibitors are being tested in the adjuvant setting. Total mesorectum excision is now the gold standard surgical technique for rectal cancer resection, and this procedure has dramatically decreased local recurrence. Nevertheless, adjuvant chemoradiotherapy is commonly indicated in the United States. In Europe, neoadjuvant radiotherapy is recommended for stage II and III resectable rectal cancers; the role of chemotherapy remains mostly investigational.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Midgley R, Kerr D: Colorectal cancer. Lancet 1999, 353:391–399.

    Article  PubMed  CAS  Google Scholar 

  2. Deans GT, Parks TG, Rowlands BJ, Spence RA: Prognostic factors in colorectal cancer. Br J Surg 1992, 79:608–613.

    Article  PubMed  CAS  Google Scholar 

  3. Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352–358.

    Article  PubMed  CAS  Google Scholar 

  4. Taal BG, Van Tinteren H, Zoetmulder FA: Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001, 85:1437–1443.

    Article  PubMed  CAS  Google Scholar 

  5. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Lancet 1995, 345:939–944.

  6. Francini G, Petrioli R, Lorenzini L, et al.: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994, 106:899–906.

    PubMed  CAS  Google Scholar 

  7. O’Connell MJ, Mailliard JA, Kahn MJ, et al.: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246–250.

    PubMed  CAS  Google Scholar 

  8. Wolmark N, Rockette H, Mamounas E, et al.: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553–3559. This NSABP randomized trial including 2151 stage II and III patients demonstrates the efficacy of the regimen and its superiority in comparison with 5-FU/levamisole-based chemotherapy.

    PubMed  CAS  Google Scholar 

  9. Haller PJ, Catalano JS, Macdonald RJ, et al.: Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: five-year final report of INT-0089 [abstract]. Proc ASCO 1998, 17:982.

    Google Scholar 

  10. QUASAR Collaborative Group: Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000, 355:1588–1596. This randomized trial shows the absence of advantage (on DFS and OS) of adding levamisole to 5-FU/LV-based chemotherapy.

    Article  Google Scholar 

  11. O’Connell MJ, Laurie JA, Kahn M, et al.: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998, 16:295–300.

    PubMed  CAS  Google Scholar 

  12. Andre T, Colin P, Louvet C, et al.: Phase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucovorin high dose in patients with Dukes B2 and C colon cancer [abstract]. Proc ASCO 2002, 21:529.

    Google Scholar 

  13. Midgley R, Kerr D: Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 2001, 10:1011–1019.

    Article  PubMed  CAS  Google Scholar 

  14. Moertel CG, Fleming TR, Macdonald JS, et al.: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995, 13:2936–2943.

    PubMed  CAS  Google Scholar 

  15. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999, 17:1356–1363.

  16. Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349–1355.

    PubMed  CAS  Google Scholar 

  17. Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196–1206. Retention of 18q allele, MSI status, and outcome after adjuvant 5-FUbased chemotherapy in stage III colon cancer are described.

    Article  PubMed  CAS  Google Scholar 

  18. Hemminki A, Mecklin JP, Jarvinen H, et al.: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000, 119:921–928.

    Article  PubMed  CAS  Google Scholar 

  19. Lenz HJ, Danenberg KD, Leichman CG, et al.: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998, 4:1227–1234.

    PubMed  CAS  Google Scholar 

  20. Salonga D, Danenberg KD, Johnson M, et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6:1322–1327.

    PubMed  CAS  Google Scholar 

  21. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al.: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998, 339:223–228.

    Article  PubMed  CAS  Google Scholar 

  22. Funaki NO, Tanaka J, Ohshio G, et al.: Cytokeratin 20 mRNA in peripheral venous blood of colorectal carcinoma patients. Br J Cancer 1998, 77:1327–1332.

    PubMed  CAS  Google Scholar 

  23. Rosenberg R, Hoos A, Mueller J, et al.: Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 2002, 20:1049–1055.

    Article  PubMed  Google Scholar 

  24. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite instability and the benefit of 5-FU based chemotherapy in stage II and III colon cancer: a pooled molecular reanalysis of randomized chemotherapy trials [abstract]. Proc ASCO 2002, 21:509.

    Google Scholar 

  25. Wolmark N, Bryant J, Smith R, et al.: Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 1998, 90:1810–1816.

    Article  PubMed  CAS  Google Scholar 

  26. Hoover HC Jr, Brandhorst JS, Peters LC, et al.: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993, 11:390–399.

    PubMed  Google Scholar 

  27. Vermorken JB, Claessen AM, Van Tinteren H, et al.: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999, 353:345–350.

    Article  PubMed  CAS  Google Scholar 

  28. Hanna MG Jr, Hoover HC Jr, Vermorken JB, et al.: Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001, 19:2576–2582.

    Article  PubMed  Google Scholar 

  29. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994, 343:1177–1183.

    Article  PubMed  CAS  Google Scholar 

  30. Riethmuller G, Holz E, Schlimok G, et al.: Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998, 16:1788–1794.

    PubMed  CAS  Google Scholar 

  31. Punt CJA, Nagy A, Douillard JY, et al.: Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study [abstract]. Proc ASCO 2001, 19:487.

    Google Scholar 

  32. Sargent DJ, Goldberg RM, Jacobson SD, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091–1097. Selected elderly patients have the same benefit of a 5-FU-based chemotherapy as do younger patients, without significant increase in toxic effects.

    Article  PubMed  CAS  Google Scholar 

  33. Popescu RA, Norman A, Ross PJ, et al.: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999, 17:2412–2418.

    PubMed  CAS  Google Scholar 

  34. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947.

    PubMed  Google Scholar 

  35. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  36. Van Cutsem E, Twelves C, Cassidy J, et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097–4106.

    PubMed  Google Scholar 

  37. Kargman SL, O’Neill GP, Vickers PJ, et al.: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995, 55:2556–2559.

    PubMed  CAS  Google Scholar 

  38. Reddy BS, Hirose Y, Lubet R, et al.: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000, 60:293–297.

    PubMed  CAS  Google Scholar 

  39. Taketo MM: COX-2 and colon cancer. Inflamm Res 1998, 47(suppl 2):S112-S116.

    Article  PubMed  CAS  Google Scholar 

  40. Giovannucci E, Rimm EB, Stampfer MJ, et al.: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994, 121:241–246.

    PubMed  CAS  Google Scholar 

  41. Giardiello FM, Hamilton SR, Krush AJ, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313–1316.

    Article  PubMed  CAS  Google Scholar 

  42. Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946–1952.

    Article  PubMed  CAS  Google Scholar 

  43. Sugarbaker PH, Gianola FJ, Speyer JC, et al.: Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985, 98:414–422.

    PubMed  CAS  Google Scholar 

  44. Vaillant JC, Nordlinger B, Deuffic S, et al.: Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg 2000, 231:449–456.

    Article  PubMed  CAS  Google Scholar 

  45. Rougier P, Sahmoud T, Nitti D, et al.: Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Intervention Oncologia, and the Japanese Foundation for Cancer Research. Lancet 1998, 351:1677–1681.

    Article  PubMed  CAS  Google Scholar 

  46. Metzger U, Mermillod B, Aeberhard P, et al.: Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality. World J Surg 1987, 11:452–458.

    Article  PubMed  CAS  Google Scholar 

  47. Gerard A, Buyse M, Nordlinger B, et al.: Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988, 208:606–614.

    Article  PubMed  CAS  Google Scholar 

  48. Heald RJ, Husband EM, Ryall RD: The mesorectum in rectal cancer surgery: the clue to pelvic recurrence? Br J Surg 1982, 69:613–616. Description of the TME surgical resection.

    Article  PubMed  CAS  Google Scholar 

  49. O’Connell MJ, Martenson JA, Wieand HS, et al.: Improving adjuvant therapy for rectal cancer by combining protractedinfusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331:502–507.

    Article  PubMed  CAS  Google Scholar 

  50. Douglass HO Jr, Moertel CG, Mayer RJ, et al.: Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986, 315:1294–1295.

    Article  PubMed  Google Scholar 

  51. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997, 336:980–987.

  52. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638–646. Short-term preoperative radiation (five 5-Gy doses) reduces the risk of local recurrence after TME.

    Article  PubMed  CAS  Google Scholar 

  53. Francois Y, Nemoz CJ, Baulieux J, et al.: Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999, 17:2396.

    PubMed  CAS  Google Scholar 

  54. van de Velde CJ: Preoperative radiotherapy and TME-surgery for rectal cancer: detailed analyses in relation to quality control in a randomized trial [abstract]. Proc ASCO 2002, 21:506.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Erasme University Hospital, Route de Lennik, 808, 1070, Brussels, Belgium

    Anne Demols MD & Jean-Luc Van Laethem MD, PhD

Authors
  1. Anne Demols MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Luc Van Laethem MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Demols, A., Van Laethem, JL. Adjuvant chemotherapy for colorectal cancer. Curr Gastroenterol Rep 4, 420–426 (2002). https://doi.org/10.1007/s11894-002-0013-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-002-0013-3

Keywords

Search

Navigation